Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 3/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311767 | 1.00 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL7014630 | 0.91 | GLS (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL844078 | 0.90 | HPGD (0.53) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL31189316 | 0.88 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL31588543 | 0.88 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL25957458 | 0.88 | NR1H2 (0.48) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL345306 | 0.88 | KDM4E (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL345307 | 0.88 | KDM4E (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL874037 | 0.88 | KDM4E (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL20024852 | 0.87 | NR1H2 (0.57) | NR1H2HPGDKDM4EPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | TEIJIN PHARMA LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4491185-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | Teijin Pharma Limited (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-119241414-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2025-01-03 | — | — | CN | disclosed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | TEIJIN PHARMA LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-4215519-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | Teijin Pharma Limited (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116075309-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2023-05-05 | — | — | CN | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | VDR, CYP24A1, AQP4 | NR1H2 84/4885HPGD 220/4885KDM4E 1262/4885 |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | NR1H2 3329/4885HPGD 1805/4885KDM4E 458/4885 |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | VDR, CYP2R1, CYP24A1 | NR1H2 284/4885HPGD 176/4885KDM4E 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.